|
| 36029412 | Patient-reported tolerability of adjuvant ipilimumab (3 or 10Â mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. | Qual Life Res | 2023 |
| 37857525 | Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. | J Immunother Cancer | 2023 |
| 37662409 | Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. | bioRxiv | 2023 |
| 37579248 | Systemic Therapy for Melanoma: ASCO Guideline Update. | J Clin Oncol | 2023 |
| 37494017 | Melanoma Detection in Alaska Native, American Indian, Asian, Black, Hispanic, and Pacific Islander Patients in a Large Skin Cancer Screening Initiative. | JAMA Dermatol | 2023 |
| 37286303 | Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. | J Immunother Cancer | 2023 |
| 37174027 | Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. | Cancers (Basel) | 2023 |
| 37435077 | Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. | Front Immunol | 2023 |
| 37397389 | Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study. | Front Oncol | 2023 |
| 36960318 | Development and Narrow Validation of Computer Vision Approach to Facilitate Assessment of Change in Pigmented Cutaneous Lesions. | JID Innov | 2023 |
| 36477181 | Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. | Clin Cancer Res | 2023 |
| 36920356 | Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. | JAMA Dermatol | 2023 |
| 36649675 | Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. | J Clin Oncol | 2023 |
| 36831449 | Immunotherapy in Melanoma: Recent Advances and Future Directions. | Cancers (Basel) | 2023 |
| 36416836 | Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35998300 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. | J Clin Oncol | 2023 |
| 35932099 | Multiple primary melanoma in association with other personal and familial cancers. | Cancer Med | 2023 |
| 36166727 | Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. | J Clin Oncol | 2023 |
| 36166093 | Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. | Clin Cancer Res | 2023 |
| 34482636 | Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. | Pigment Cell Melanoma Res | 2022 |
| 35587532 | Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. | Cancer Immunol Res | 2022 |
| 35385051 | Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. | JAMA Dermatol | 2022 |
| 35709414 | Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. | J Clin Oncol | 2022 |
| 35583689 | Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. | Ann Surg Oncol | 2022 |
| 35579997 | Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. | Clin Cancer Res | 2022 |
| 35659704 | Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. | J Transl Med | 2022 |
| 35551967 | A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. | J Am Acad Dermatol | 2022 |
| 36505793 | Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma. | Front Oncol | 2022 |
| 36600653 | Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. | J Immunother Cancer | 2022 |
| 36202690 | Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. | Eur J Cancer | 2022 |
| 36356143 | TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma. | Science | 2022 |
| 36265502 | Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. | Lancet Oncol | 2022 |
| 36291758 | Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma. | Cancers (Basel) | 2022 |
| 36011010 | Targeted Long-Read Bisulfite Sequencing Identifies Differences in the <i>TERT</i> Promoter Methylation Profiles between <i>TERT</i> Wild-Type and <i>TERT</i> Mutant Cancer Cells. | Cancers (Basel) | 2022 |
| 35879777 | Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. | J Transl Med | 2022 |
| 35319783 | Poorer survival outcomes in patients with multiple versus single primary melanoma. | Cancer | 2022 |
| 35074904 | Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. | J Immunother Cancer | 2022 |
| 35316223 | Tim-3 mediates T cell trogocytosis to limit antitumor immunity. | J Clin Invest | 2022 |
| 35013003 | Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. | Cancer Immunol Res | 2022 |
| 34764195 | Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. | Cancer Discov | 2022 |
| 33414132 | The State of Melanoma: Emergent Challenges and Opportunities. | Clin Cancer Res | 2021 |
| 33796406 | A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. | Oncoimmunology | 2021 |
| 33542131 | Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. | Science | 2021 |
| 33871399 | Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases. | Melanoma Res | 2021 |
| 33759768 | State of Melanoma: An Historic Overview of a Field in Transition. | Hematol Oncol Clin North Am | 2021 |
| 33732652 | Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma. | Front Oncol | 2021 |
| 33898322 | GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. | Front Oncol | 2021 |
| 33613873 | Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. | J Extracell Vesicles | 2021 |
| 33753453 | Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. | Clin Cancer Res | 2021 |
| 33557083 | Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in Youth. | J Clin Med | 2021 |